Pharmaceutical Price Transparency Should Be Policy Goal - Schondelmeyer
Executive Summary
Policy making efforts should focus on pharmaceutical price transparency as a method to lower drug costs, PRIME Institute Director Stephen Schondelmeyer, PhD, told the HHS conference on drug pricing Aug. 8 in Washington, D.C.
You may also be interested in...
Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
Medco/Reader's Digest Consumer PBM Plan Offers 18% Discount On Mail Rxs
The Merck-Medco/Reader's Digest consumer discount plan offers enrollees an average discount of 18% for mail-service prescriptions, Merck-Medco said.
Senior Coverage Increases Per Capita Drug Spend By 66%, HHS Report Finds
Average per capita spending on drugs for Medicare eligibles with drug insurance was 66% higher in 1996 than spending on pharmaceuticals for non-covered elderly, according to an analysis of drug spending released by the Clinton Administration on April 10.